Iran’s Innovative Biotech Revolution: Expanding Reach to 35 Global Markets

Since the beginning of the current Iranian year on March 19, 2024, the export of biotechnology products from Iran has seen significant growth, reaching 35 countries globally, an increase from 33 countries in the previous year. This surge highlights the country’s growing capabilities in the pharmaceutical biotechnology sector.

According to IRNA, Hossein Amirazodi, the secretary general of the association of pharmaceutical biotechnology producers and exporters, shared these insights during the 4th International Conference and Exhibition on Iranian Medical Biotech Products and Related Industries (Iran Bio). This event is taking place from February 4 to 6 at the Olympic Hotel in Tehran.

Amirazodi noted that the pharmaceutical biotechnology industry saves approximately two billion dollars in foreign currency annually, accounting for about 60% of Iran’s total pharmaceutical exports. He emphasized the following points regarding the current state of the industry:

• Iran successfully produces 40 out of 150 pharmaceutical biotechnology products available worldwide.
• This achievement has been realized over the past 30 years.
• The Iran Bio event aims to showcase the capabilities and potential of national biotechnology industries.
• It also serves as a platform for technology transfer and collaboration among researchers and industry experts.

Furthermore, the conference is designed to exhibit the latest advancements in biotechnology and support domestic manufacturers by expanding market access and export opportunities.

In addition to the advancements in biotechnology, the first half of the current Iranian year, which commenced on March 20, has shown promising results in medicine exports. The country has exported medicines worth 104.6 million dollars, marking a year-on-year increase of 19.7%. The total export volume reached 49,400 tons, demonstrating a 15% rise compared to the same timeframe last year, as reported by the Islamic Republic of Iran’s Customs Administration.

During this six-month period, approximately 345 companies have been actively involved in the production of medicines, supplements, and raw materials, while also managing pharmaceutical imports.

In terms of imports, pharmaceutical companies brought in a total of 54,800 tons of goods valued at 1.1 billion dollars. This reflects a 3.76% decrease in quantity but a 4.5% increase in value compared to the previous year, according to IRNA.

In June 2024, Seyyed Ali Maboudi, an official with the Food and Drug Administration (FDA), announced plans to boost pharmaceutical exports by 30% in the mid-term. He stated, “In the past years, medicine exports in Iran accounted for a small share of non-oil exports. However, over the past year, it experienced a growing trend.”

The developments in the Iranian biotechnology sector and the increasing trend in pharmaceutical exports signify a robust potential for growth and innovation in the industry. This positive trajectory not only enhances Iran’s position in the global market but also contributes to the country’s economic stability and resilience.

As the biotechnology landscape continues to evolve, events like Iran Bio play a crucial role in fostering collaboration, showcasing innovations, and expanding market reach for Iranian products. The commitment to enhancing pharmaceutical exports and prioritizing biotechnology development reflects a strategic approach towards achieving sustainability and self-sufficiency in the healthcare sector.

In conclusion, the advancements in biotechnology exports and the increase in medicine exports highlight a thriving industry that is set to make significant contributions to Iran’s economy. As more countries recognize the quality and efficacy of Iranian biotechnology products, there will likely be a continued upward trend, benefiting both the domestic market and international partnerships.